No headlines found.
PRNewswire (Thu, 29-Jan 5:05 PM ET)
Business Wire (Thu, 8-Jan 7:00 AM ET)
Business Wire (Fri, 5-Dec 9:00 AM ET)
Business Wire (Tue, 11-Nov 6:00 PM ET)
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Amylyx Pharmaceuticals trades on the NASDAQ stock market under the symbol AMLX.
As of February 10, 2026, AMLX stock price climbed to $14.94 with 444,205 million shares trading.
AMLX has a beta of 0.96, meaning it tends to be less sensitive to market movements. AMLX has a correlation of 0.06 to the broad based SPY ETF.
AMLX has a market cap of $1.59 billion. This is considered a Small Cap stock.
In the last 3 years, AMLX traded as high as $38.32 and as low as $1.58.
The top ETF exchange traded funds that AMLX belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWO.
AMLX has outperformed the market in the last year with a return of +293.2%, while the SPY ETF gained +16.6%. In the last 3 month period, AMLX beat the market returning +21.4%, while SPY returned +3.6%. However, in the most recent 2 weeks AMLX has underperformed the stock market by returning -0.5%, while SPY returned +0.1%.
AMLX support price is $13.46 and resistance is $14.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMLX shares will trade within this expected range on the day.